These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 2440170

  • 1. [Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer].
    Fornara P, Sturm W, Fabricius PG, Schmiedt E.
    Urologe A; 1987 May; 26(3):158-61. PubMed ID: 2440170
    [Abstract] [Full Text] [Related]

  • 2. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA, Ekman PE, Blankenstein MA, Cooper EH, Kontturi M, Lilja H, Oesterling JE, Stenman UH, Turkes A.
    Scand J Urol Nephrol Suppl; 1994 May; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [Abstract] [Full Text] [Related]

  • 3. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A, Simşek F, Ilker Y, Türkeri L, Ercan H.
    Int Urol Nephrol; 1993 May; 25(3):271-8. PubMed ID: 7693607
    [Abstract] [Full Text] [Related]

  • 4. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
    Théodon P, Rymer JC, Chopin D, Kouyoudjian JC, Abbou CC, Auvert J.
    Ann Urol (Paris); 1988 May; 22(3):199-205. PubMed ID: 2456713
    [Abstract] [Full Text] [Related]

  • 5. [Pathological basis for elevation of serum prostate specific antigen].
    Xia TL, Deng FM, Feng T.
    Zhonghua Yi Xue Za Zhi; 1994 May; 74(5):306-8, 327. PubMed ID: 7525028
    [Abstract] [Full Text] [Related]

  • 6. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 7. [Prostate-specific antigen. A new marker of prostatic pathology].
    Boccon-Gibod L, Géraud M, Dugué MA.
    Ann Urol (Paris); 1988 Mar; 22(3):206-10. PubMed ID: 2456714
    [Abstract] [Full Text] [Related]

  • 8. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA, Kamalov AA, Karpov VK, Riaboĭ AV, Prokhorov AV.
    Urologiia; 2001 Mar; (2):37-40. PubMed ID: 11490716
    [Abstract] [Full Text] [Related]

  • 9. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM.
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [Abstract] [Full Text] [Related]

  • 10. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV, Chen I, Qayyum A, Westphalen AC, Carroll PR, Hricak H, Chen MH, Kurhanewicz J.
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [Abstract] [Full Text] [Related]

  • 11. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, Wright GL, Schellhammer PF, Weigand RA, Olson RM, Dowell BL, Borden KK, Oesterling JE.
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [Abstract] [Full Text] [Related]

  • 12. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y, Ozono S, Kagebayashi Y, Yoshi M, Tani Y, Uemura H, Momose H, Okajima E.
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Anatomoclinical and biologic correlations in prostatic pathology. Apropos of 150 case reports].
    Amiel J, Chevallier D, Peyrottes A, Benoliel J, Toubol J.
    Ann Urol (Paris); 1989 Oct; 23(6):528-30. PubMed ID: 2482700
    [Abstract] [Full Text] [Related]

  • 15. [Tumor markers in prostate cancer].
    Kuriyama M.
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1915-22. PubMed ID: 7521999
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Determination of tumor markers in the diagnosis of prostatic cancer].
    Casas Terrón E, Mari Ruiz M, Molina Andreu E.
    Arch Esp Urol; 1993 Mar; 46(2):99-103. PubMed ID: 7684585
    [Abstract] [Full Text] [Related]

  • 18. Prostate specific antigen as tumor marker: relationship with histologic grading.
    Xess A, Singh M, Raghwendra KH, Sharma HP, Shahi SK.
    Indian J Pathol Microbiol; 2001 Jul; 44(3):261-4. PubMed ID: 12024909
    [Abstract] [Full Text] [Related]

  • 19. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H, Koide T, Kuriyama M, Ban Y, Deguchi T, Kawada Y.
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [Abstract] [Full Text] [Related]

  • 20. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
    Morote Robles J, de Torres Mateos JA.
    Arch Esp Urol; 1989 Jul; 42 Suppl 2():124-30. PubMed ID: 2484148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.